Every Form 4 that Rapport Therapeutics, Inc. (RAPP) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow RAPP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RAPP filings page.
Rapport Therapeutics, Inc. (RAPP) reported an insider stock sale by an executive officer. The reporting person, who serves as Chief Scientific Officer, filed a Form 4 showing two open-market sales of common stock on 11/17/2025.
The executive sold 3,156 shares of common stock at a weighted average price of $24.8399, followed by an additional 5,344 shares at a weighted average price of $25.3922. After these transactions, the officer beneficially owns 401,142 shares of Rapport Therapeutics common stock in direct ownership form.
The filing explains that these transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 12, 2024, which is designed to allow insiders to sell shares according to predetermined instructions.